ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0838

Is SARS-CoV-2 Associated with Worse Outcomes After Total Knee Arthroplasty?

Lisa Mandl1, Benjamin Swett1, Robyn Lipschultz1, Myriam Lin1, Alison Zhao2, Carola Hanreich1, Dongmei Sun1, Kethy Jules-elysee1 and Friedrich Boettner1, 1Hospital for Special Surgery, New York, NY, 2Cleveland Clinic Lerner College of Medicine, Cleveland, OH

Meeting: ACR Convergence 2022

Keywords: Arthroplasty, COVID-19, Osteoarthritis, pain, Patient reported outcomes

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Orthopedics, Low Back Pain, and Rehabilitation Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Over 520 million people have been infected by SARS-CoV-2. In 10-40%, disabling symptoms such as fatigue and dyspnea can persist. Risk factors for poor outcomes after both COVID19 and total knee arthroplasty (TKA) are similar. To our knowledge, whether previous SARS-CoV-2 infection is associated with poor outcomes after TKA has never been evaluated.

Methods: Patients with knee osteoarthritis (KOA) undergoing TKA were recruited from a single center between 10/2020 and 10/2021. Patients were screened pre-operatively for SARS-CoV-2 infection with a serum nucleocapsid IgG. SARS-CoV-2 IgG +ve patients were matched with SARS-CoV-2 IgG -ve patients without self-reported COVID19 on age (+/- 5 years), surgeon volume (< 50 TKA annually vs. > 50), and body mass index (BMI kg/m2 < 35 vs. > 35). Data were collected pre-operatively and at 6 months.

Results: 144/171 (67 SARS-CoV-2 IgG +ve cases and 77 SARS-CoV-2 IgG -ve controls) had baseline and 6-month data. Age 64 years (SD 7.8), women 58.3%, BMI 31.8 kg/m2 (SD 5.9), White 80.6%. 43/67 cases reported having had clinical symptoms attributed to COVID19, with a mean of 233.4 days (SD 125.6, range 17 – 444) between clinical COVID19 and TKA. Pre-operatively, there were no clinically meaningful differences in PROMIS-29 or KOOS scores between those with and without previous SARS-CoV-2 infection (Table 2). 6 months after TKA, there was similarly no difference in PROMIS-29, PROMIS Dyspnea, KOOS scores, or satisfaction with TKA between those with and without previous SARS-CoV-2. Among cases, there was no difference in KOOS or PROMIS-29 scores at 6-month comparing those with 0, 1-4 or > 5 COVID19 symptoms. There were, however, statistically significant Spearman correlations between time from clinical COVID19 to TKA and 6-month KOOS Pain (r=0.38 p=0.01), KOOS Function (r= 0.36 p=0.02), KOOS Symptoms (r=0.34 p=0.03), and PainDetect (r= -0.49 p=0.0013). Mean 6-month PainDetect scores were significantly lower in subjects with > 1 year between clinical COVID19 and TKA, (4.1 vs. 7.7 p=0.016). 4 subjects had neuropathic pain at 6 months; the 2 cases both had TKA < 300 days after COVID19. 1 of 2 controls had COVID19 post-TKA.

Conclusion: Previous SARS-CoV-2 infection was not associated with worse pain or function 6 months after TKA. However, a shorter time between TKA and clinical COVID19 was correlated with worse pain and function 6 months after TKA. Larger studies are needed to evaluate whether high-risk patients may benefit from delaying elective TKA 10-12 months after COVID19.

Supporting image 1

Supporting image 2

PROMIS_29: T-Scores: range 0_100; 50= population mean. Higher=more of the domain being measured
KOOS Subscales: 0_100; higher is better
PainDetect: _1_38; >19= neuropathic pain


Disclosures: L. Mandl, Pfizer; B. Swett, None; R. Lipschultz, None; M. Lin, Pfizer, Hospital for Special Surgery Academy of Medical Educators; A. Zhao, None; C. Hanreich, None; D. Sun, None; K. Jules-elysee, None; F. Boettner, Smith and Nephew, Ortho Development.

To cite this abstract in AMA style:

Mandl L, Swett B, Lipschultz R, Lin M, Zhao A, Hanreich C, Sun D, Jules-elysee K, Boettner F. Is SARS-CoV-2 Associated with Worse Outcomes After Total Knee Arthroplasty? [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/is-sars-cov-2-associated-with-worse-outcomes-after-total-knee-arthroplasty/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-sars-cov-2-associated-with-worse-outcomes-after-total-knee-arthroplasty/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology